<DOC>
	<DOCNO>NCT01386970</DOCNO>
	<brief_summary>This study evaluate blood blood cell concentration zidovudine lamivudine men versus woman versus without HIV infection . Additionally , marker side effect correlate blood level drug . The hypothesis woman HIV would higher drug level , well marker side effect .</brief_summary>
	<brief_title>Effect Gender HIV Infection Zidovudine Lamivudine Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Documented physiciandiagnosed HIVinfection ( HIV+ antibody plasma HIVRNA+ ) ; HIVnegative volunteer must negative HIVELISA . Age 18 55 year ; Either antiretroviral na√Øve , HIVtherapy precede 6 month ; Planned antiretroviral regimen include standard dos ZDV plus 3TC part antiretroviral regimen . Once twicedaily 3TC allow . Any medical condition opinion investigator would jeopardize intent study . In opinion investigator , concomitant immunomodulatory medication , chemotherapeutic agent , investigational drug , alternative therapy , include , glucocorticoid , recombinant growth factor cytokine ( e.g . Granulocytemacrophage colonystimulating factor , Granulocyte colonystimulating factor , interferonalpha gamma , human growth hormone , etc ) , ribavirin , birthcontrol pill , sex hormone could interfere cellular pharmacology study medication ; Concomitant medication interfere renal drug clearance include , tenofovir , adefovir , cidofovir , ganciclovir , probenecid , similarly problematic medication opinion investigator ; Concomitant warfarin daily aspirin ( prevent excess bleed biopsy ) . Pregnancy plan become pregnant , menopause ; Any &gt; = grade II abnormality hemoglobin , absolute neutrophil count , routine liver function test , serum creatinine , organ function abnormality . Any medical personal condition , judgment investigator , may influence subject 's ability comply study condition , active mental illness , plan leave geographical area . Inability give inform consent . Triple nucleoside analog reverse transcriptase regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>antiretroviral therapy</keyword>
	<keyword>nucleoside analog</keyword>
	<keyword>mitochondrial toxicity</keyword>
	<keyword>clinical pharmacology</keyword>
	<keyword>cellular pharmacology</keyword>
	<keyword>pharmacogenetics</keyword>
</DOC>